Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
9.780
+0.140 (+1.45%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
38
39
Next >
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
June 27, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference
June 21, 2023
Via
Investor Brand Network
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
June 21, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Upcoming H.C. Wainwright Neuropsychiatry Conference
June 15, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development
June 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Inc. Provides Corporate Update
June 08, 2023
From
Cybin Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
June 06, 2023
On Tuesday, 69 stocks hit new 52-week lows.
Via
Benzinga
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
June 06, 2023
Major Investor Commits $30 Million To Psychedelics Funding
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team
June 05, 2023
Via
Investor Brand Network
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
June 05, 2023
From
Cybin Inc.
Via
Business Wire
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies Healthcare Conference
June 01, 2023
Via
Investor Brand Network
Cybin to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Cybin Inc.
Via
Business Wire
Major Investor Commits $30M To Psychedelics Funding
May 31, 2023
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30...
Via
Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M
May 31, 2023
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
May 30, 2023
From
Cybin Inc.
Via
Business Wire
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
May 24, 2023
Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
May 24, 2023
Via
Investor Brand Network
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
May 24, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
May 09, 2023
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug...
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
May 09, 2023
Via
Investor Brand Network
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
May 09, 2023
From
Cybin Inc.
Via
Business Wire
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
April 28, 2023
Via
Investor Brand Network
Cybin to Participate at the 26th Annual Milken Institute Global Conference
April 28, 2023
From
Cybin Inc.
Via
Business Wire
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.